• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[生活方式相关疾病与骨代谢的最新进展。特立帕肽用于治疗与生活方式相关疾病相关的骨质疏松症]

[Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].

作者信息

Fukumoto Seiji

机构信息

Division of Nephrology & Endocrinology, Department of Medicine, University of Tokyo Hospital, Japan.

出版信息

Clin Calcium. 2014 Nov;24(11):1701-5.

PMID:25355155
Abstract

Teriparatide is a peptide with 34 amino acids that corresponds to N-terminal portion of parathyroid hormone (PTH) . Teriparatide is the only anabolic agent currently available and prevent fractures by increasing bone mass and improving bone architecture. PTH and bone turnover are reported to be low in some patients with type 2 diabetes and chronic kidney disease. For these patients, it seems to be theoretically reasonable to use teriparatide. However, it has not been shown that teriparatide is more effective for patients with low bone turnover than other subjects.

摘要

特立帕肽是一种由34个氨基酸组成的肽,相当于甲状旁腺激素(PTH)的N端部分。特立帕肽是目前唯一可用的促合成代谢药物,通过增加骨量和改善骨结构来预防骨折。据报道,一些2型糖尿病和慢性肾病患者的PTH和骨转换率较低。对于这些患者,使用特立帕肽在理论上似乎是合理的。然而,尚未证明特立帕肽对骨转换率低的患者比其他受试者更有效。

相似文献

1
[Updates on Lifestyle-Related Diseases and Bone Metabolism. Teriparatide for osteoporosis associated with lifestyle-related diseases].[生活方式相关疾病与骨代谢的最新进展。特立帕肽用于治疗与生活方式相关疾病相关的骨质疏松症]
Clin Calcium. 2014 Nov;24(11):1701-5.
2
Parathyroid hormone as an anabolic skeletal therapy.甲状旁腺激素作为一种骨骼合成代谢疗法。
Drugs. 2005;65(17):2481-98. doi: 10.2165/00003495-200565170-00005.
3
Indications to teriparatide treatment in patients with osteoporosis.骨质疏松症患者使用特立帕肽治疗的适应证。
Swiss Med Wkly. 2011 Nov 7;141:w13297. doi: 10.4414/smw.2011.13297. eCollection 2011.
4
[The Importance of teriparatide in the treatment of osteoporosis].[特立帕肽在骨质疏松症治疗中的重要性]
Clin Calcium. 2016 Jun;26(6):905-13.
5
Anabolic therapies for osteoporosis.骨质疏松症的合成代谢治疗。
Endocrinol Metab Clin North Am. 2012 Sep;41(3):507-25. doi: 10.1016/j.ecl.2012.05.002. Epub 2012 Jun 20.
6
[Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].甲状旁腺激素(特立帕肽)对骨质疏松症骨量和骨质量的影响
Nihon Rinsho. 2011 Jul;69(7):1264-9.
7
[PTH preparations].[甲状旁腺激素制剂]
Nihon Rinsho. 2015 Oct;73(10):1696-700.
8
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.特立帕肽治疗期间骨折风险的降低与治疗前的骨转换无关。
Bone. 2006 Aug;39(2):237-43. doi: 10.1016/j.bone.2006.02.003. Epub 2006 Mar 24.
9
[Daily subcutaneous injection of teriparatide : the progress and current issues].[特立帕肽每日皮下注射:进展与当前问题]
Clin Calcium. 2014 Jan;24(1):35-43.
10
[Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].[重组甲状旁腺激素治疗重度骨质疏松症——病例系列]
Przegl Lek. 2011;68(7):391-5.